Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



No Approval for You ... Yet

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Some seven months ago, I called Eli Lilly's (NYSE: LLY  ) and Daiichi Sankyo's submission of top pipeline drug prasugrel the most interesting FDA review of 2008. Alas, the FDA must not have been reading. Prasgurel's approval has been delayed. Again.

After the markets closed on Friday, Lilly announced that the agency was still reviewing its application. Prasugrel, which will go by the brand name Effient, is Lilly and partner Daiichi Sankyo's attempt to compete with Sanofi-Aventis' (NYSE: SNY  ) and Bristol-Myers Squibb's (NYSE: BMY  ) blockbuster compound Plavix in the field of anticoagulant acute coronary syndrome heart drugs.

When the companies submitted prasugrel as a New Drug Application in Dec. 2007, they received a priority review designation from the FDA, reserved for drugs that could represent a "significant therapeutic or public health advance" if approved. The agency set June 26 as its goal for a PDUFA date to make a marketing decision on the drug.

When June rolled around, the FDA issued a three-month extension to its review, which pushed it back to last Friday. And now that Friday's passed the FDA by, Lilly is giving no new timeline for when it expects a decision, except to say that "the review is very far along."

The FDA has been delaying its approval decisions on most drug candidates this year. Many drugmakers have seen delays of several months, with the most extreme case being Cardiome's (Nasdaq: CRME  ) nearly seven-month delay for a decision on its atrial fibrillation drug Kynapid. A lucky few, like Genentech (NYSE: DNA  ) , have seen no FDA delay in reviewing their marketing applications.

With the FDA's new drug review delays now hitting even priority review drugs like prasugrel, investors should expect all new drugs (perhaps excluding a few indications like cancer or HIV) to be hit with FDA delays. Price this into your estimates.

If prasugrel is eventually approved, it will likely have several months less in which to market it, depending on how used-up its patents are. While the delay is undoubtedly a negative, for a diversified large-cap pharma like Eli Lilly, it shouldn't be a major issue -- unless the FDA pulls another Cardiome.

Eli Lilly is an active Income Investor pick. Try any of our Foolish newsletters today free for 30 days.

Fool contributor Brian Lawler does not own shares of any company mentioned in this article. The Fool has an A+ disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 741247, ~/Articles/ArticleHandler.aspx, 10/23/2016 2:08:01 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
CRME $3.01 Down -0.04 -1.31%
Cardiome Pharma CAPS Rating: *
DNA $94.97 Down +0.00 +0.00%
Genentech CAPS Rating: ****
SNY $37.75 Down -0.32 -0.84%
Sanofi CAPS Rating: *****